Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series was written by Mahdaviani, Seyed Alireza;Fallahi, Mazdak;Jamee, Mahnaz;Marjani, Majid;Tabarsi, Payam;Moniri, Afshin;Farnia, Parisa;Daneshmandi, Zahra;Parvaneh, Nima;Casanova, Jean-Laurent;Bustamante, Jacinta;Mansouri, Davood;Velayati, Ali Akbar. And the article was included in Annals of Clinical Microbiology and Antimicrobials in 2022.SDS of cas: 13292-46-1 This article mentions the following:
Post-vaccination BCG disease typically attests to underlying inborn errors of immunity (IEIs), with the highest rates of complications in patients with Mendelian susceptibility to mycobacterial disease (MSMD). However, therapeutic protocols for the management of BCG-osis (disseminated) and persistent BCG-itis (localized) are still controversial. Twenty-four Iranian patients with MSMD (BCG-osis or BCG-itis), followed from 2009 to 2020 in Tehran, were included in the study. Their medical records were retrospectively reviewed for demographics, clin. features, laboratory findings, and mol. diagnosis. The therapeutic protocol sheets were prepared to contain the types and duration of anti-mycobacterial agents. BCG disease either as BCG-itis (33.3%) or BCG-osis (66.7%) was confirmed in all patients by pos. gastric washing test (54.2%), microbial smear and culture (58.3%), or purified protein derivative (PPD) test (4.2%). The duration between BCG-osis onset and MSMD diagnosis was 21.6 mo. All except three patients were initiated on second-line anti-mycobacterial agents with either a fluoroquinolone (levofloxacin: 15 mg/kg/day, ciprofloxacin: 20 mg/kg/day, ofloxacin: 15 mg/kg/day), aminoglycoside (amikacin: 10-15 mg/kg/day, streptomycin: 15 mg/kg/day), and/or macrolide (clarithromycin: 15 mg/kg/day) along with oral rifampin (10 mg/kg/day), isoniazid (15 mg/kg/day), and ethambutol (20 mg/kg/day). Three patients showed a clin. response to rifampin, despite in vitro resistance. Fourteen (58.3%) patients received also adjuvant s.c. IFN-纬 therapy, 50渭/m2 every other day. At the end of survey, most patients (n = 22, 91.7%) were alive and two patients died following BCG-osis and respiratory failure. We recommend the early instigation of second-line anti-mycobacterial agents in MSMD patients with BCG disease. In the experiment, the researchers used many compounds, for example, 8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1SDS of cas: 13292-46-1).
8-(n-(4-methyl-1-piperazinyl)formidoyl)-rifomycins (cas: 13292-46-1) belongs to piperazine derivatives. Industrial applications of piperazine include the manufacture of plastics, resins, pesticides and brake fluids. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.SDS of cas: 13292-46-1
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics